These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29263255)

  • 1. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
    Leoni V; Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
    Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
    J Virol; 2017 May; 91(10):. PubMed ID: 28250120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
    Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
    J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors.
    Gatta V; Petrovic B; Campadelli-Fiume G
    PLoS Pathog; 2015 May; 11(5):e1004907. PubMed ID: 25996983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
    Menotti L; Avitabile E; Gatta V; Malatesta P; Petrovic B; Campadelli-Fiume G
    Viruses; 2018 Jun; 10(7):. PubMed ID: 29966356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
    Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
    Campadelli-Fiume G; Petrovic B; Leoni V; Gianni T; Avitabile E; Casiraghi C; Gatta V
    Viruses; 2016 Feb; 8(3):63. PubMed ID: 26927159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
    Menotti L; Cerretani A; Hengel H; Campadelli-Fiume G
    J Virol; 2008 Oct; 82(20):10153-61. PubMed ID: 18684832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.
    Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
    PLoS Pathog; 2017 Apr; 13(4):e1006352. PubMed ID: 28423057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rethinking herpes simplex virus: the way to oncolytic agents.
    Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
    Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
    Shibata T; Uchida H; Shiroyama T; Okubo Y; Suzuki T; Ikeda H; Yamaguchi M; Miyagawa Y; Fukuhara T; Cohen JB; Glorioso JC; Watabe T; Hamada H; Tahara H
    Gene Ther; 2016 Jun; 23(6):479-88. PubMed ID: 26905369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line.
    Vannini A; Leoni V; Sanapo M; Gianni T; Giordani G; Gatta V; Barboni C; Zaghini A; Campadelli-Fiume G
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
    Menotti L; Nicoletti G; Gatta V; Croci S; Landuzzi L; De Giovanni C; Nanni P; Lollini PL; Campadelli-Fiume G
    Proc Natl Acad Sci U S A; 2009 Jun; 106(22):9039-44. PubMed ID: 19458262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
    Leoni V; Vannini A; Gatta V; Rambaldi J; Sanapo M; Barboni C; Zaghini A; Nanni P; Lollini PL; Casiraghi C; Campadelli-Fiume G
    PLoS Pathog; 2018 Aug; 14(8):e1007209. PubMed ID: 30080893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
    Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
    Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.
    Menotti L; Cerretani A; Campadelli-Fiume G
    J Virol; 2006 Jun; 80(11):5531-9. PubMed ID: 16699034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B Virus (Macacine Herpesvirus 1) Divergence: Variations in Glycoprotein D from Clinical and Laboratory Isolates Diversify Virus Entry Strategies.
    Patrusheva I; Perelygina L; Torshin I; LeCher J; Hilliard J
    J Virol; 2016 Oct; 90(20):9420-32. PubMed ID: 27512063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
    Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
    Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of herpesviruses as oncolytic agents.
    Menotti L; Campadelli-Fiume G; Nanni P; Lollini PL; De Giovanni C
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.